Objective:To analyze the clinical diagnosis and treatment process of liver injury and diarrhea caused by crizotinib in one patient with non-small cell lung cancer(NSCLC),and provide a reference for the clinically safe medication of crizotinib.Methods and Results:The patient received chemotherapy for NSCLC.During the chemotherapy,the patient developed symptoms such as fatigue and nausea 15 days after taking crizotinib,and the liver function test results showed significant abnormalities in alanine aminotransferase and aspartate aminotransferase.After investigating the patient's medical history and medication history,the clinical pharmacist believed that the liver injury was possibly related to crizotinib,and suggested doctors to discontinue crizotinib and provide liver protection therapy and the doctors accepted the suggestion.One week later,the patient's liver function basically returned to normal;afterwards,the patient used crizotinib again on the basis of liver protection therapy.Although there was no abnormal liver function,diarrhea symptoms occurred 2 months later.The clinical pharmacist believed that it was still possibly related to crizotinib,and suggested using lorlatinib instead.The doctors accepted the suggestion;3 days later,the patient's diarrhea symptoms were completely relieved.Conclusion:For patients using anti-tumor drugs such as crizotinib that may induce more adverse reactions,clinicians and pharmacists should strength the relevant monitoring and give instructions for safe medication,so as to detect and handle them early and guarantee the medication safety for patients.
关键词
克唑替尼/肝损伤/腹泻/非小细胞肺癌/药物不良反应
Key words
crizotinib/liver injury/diarrhea/non-small cell lung cancer/adverse drug reactions
维普
万方数据